Enalapril

01/01/1993 - "Enalapril and high-dose DuP were almost equally effective in controlling systemic hypertension. "
06/01/1986 - "In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained delta P at near-normal levels without significant reduction in SNGFR and QA. "
12/01/1984 - "In conclusion, enalapril monotherapy reduces blood pressure in two-thirds of patients with moderately severe essential hypertension at rest and during exercise, associated with a significant reduction in TPRI. "
10/01/1982 - "From these results it is concluded that MK 421 is a strong and long-acting antihypertensive drug and its clinical application seems very useful for the treatment of hypertension."
01/01/1985 - "Multiclinic controlled studies have shown that enalapril alone 10 to 40 mg/day orally is effective in lowering blood pressure in patients with essential hypertension. "

04/01/1983 - "In conclusion, the long-acting converting enzyme inhibitor, enalapril, was effective in patients with chronic congestive heart failure; however, additional studies will be necessary to further delineate the optimal dose range and identify those patients who are most likely to respond to the drug."
05/03/2001 - "Despite similar doses of drug in the two groups, enalapril therapy, as compared with placebo, was associated with a 44 percent reduction (95 percent confidence interval, 27 to 57 percent) in the risk of hospitalization for heart failure among the white patients (P<0.001) but with no significant reduction among black patients (P=0.74). "
12/01/1993 - "The effect of enalapril on mortality and hospitalization for heart failure was significantly greater for patients with the lowest ejection fraction. "
07/01/1991 - "The acute efficacy of rapid loading of oral long-acting enalapril in congestive heart failure remains to be established. "
07/11/1988 - "There was a significant improvement in New York Heart Association classification in the enalapril group, together with a reduction in heart size and a reduced requirement for other heart failure medication. "

09/01/2014 - "The conversion to enalapril resulted in a significant reduction in proteinuria. "
01/01/2001 - "Both drugs reduced proteinuria, but enalapril was more effective in protecting the renal function. "
10/01/2013 - "Enalapril is effective in reducing proteinuria in children with CKD and might be renoprotective in proteinuric CKD."
01/01/1999 - "Enalapril improved proteinuria in comparison with the Nx group (NxE 5.6+/-0.6 mg/24 h vs. Nx 16.1+/-3.4 mg/24 h, p<0.05). "
02/01/1996 - "It was concluded that: (1) CsA lowers proteinuria in MN in part, by enhancing barrier size-selectivity; (2) lack of comparable efficacy of enalapril suggests that the antiproteinuric effect of CsA is related to its immuno-suppressive rather than glomerulodepressor properties; but (3) judged by repeat biopsy, CsA does not prevent continuing autoantibody formation in this disorder."

01/01/2011 - "Treatment of SNX with enalapril from week 8-12 significantly improved myocardial fibrosis (1.63±0.25%, p<0.05), but not capillary reduction (3908±486 mm/mm(3)) or increased intercapillary distance. "
06/01/1994 - "These results indicate that enalapril treatment ameliorates the tubulointerstitial fibrosis of the affected kidney in UUO. "
09/01/2012 - "The present study examines the possible beneficial effects of enalapril on the development of diabetes associated fibrosis and DNA damage in rats. "
01/01/2003 - "This study confirms that enalapril inhibits the interstitial fibrosis in UUO kidneys. "
05/01/2015 - "Renal cell proliferation and apoptosis, glomerulosclerosis, and tubulointerstitial fibrosis were all increased by enalapril (P<0.05). "

02/01/2002 - "Improved fibrinolysis after one year of treatment with enalapril in men and women with uncomplicated myocardial infarction."
07/01/2007 - "1. The aim of the present study was to evaluate the effect of treatment with enalapril on the sensitivity of cardiopulmonary reflexes 30 days after myocardial infarction in Wistar rats. "
06/01/2003 - "In the ABCD study, enalapril treatment was associated with a lower risk of myocardial infarction. "
10/01/1999 - "This study demonstrated that administration of enalapril reduces the increased procoagulant activity in patients with myocardial infarction associated with inhibition of the activation and accumulation of macrophages and monocytes."
10/01/1999 - "In a randomized, double-blind, placebo-controlled study beginning about two weeks after myocardial infarction, 16 patients received four weeks of placebo (placebo group) and another 16 patients received four weeks of enalapril 5 mg daily therapy (enalapril group). "